Transaction DateRecipientSharesTypePriceValue
3rd June 2020Michael Bigham5,000Grant/award etc.$0.00
18th May 2020Robert S Radie31,000Grant/award etc.$0.00
12th May 2020Adam Woodrow4,798Open or private sale$4.75$22,790.50
12th May 2020William M. Haskel4,666Open or private sale$4.75$22,163.50
12th May 2020Evan Loh9,595Open or private sale$4.75$45,576.25
12th May 2020Michael Bigham12,250Open or private sale$4.68$57,330.00
12th May 2020Randall B. Brenner6,198Open or private sale$4.75$29,440.50
31st March 2020Robert S Radie3,689Grant/award etc.$0.00
16th March 2020Thomas John Dietz1,000Open or private purchase$4.95$4,950.00
12th March 2020Thomas John Dietz5,000Grant/award etc.$0.00
Transcept Pharmaceuticals
Transcept Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.



Ticker: TSPT
Sector: Unknown
Industry: Unknown
SEC Central Index Key (CIK): 1178711
Employees:
Exchange: None
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $142 M (0%)
Inventory, Net: $18 M (0%)
Assets, Current: $222 M (-8%)
Property, Plant and Equipment, Net: $976 Th (0%)
Other Assets, Noncurrent: $148 Th (0%)
Assets: $227 M (-9%)
Accounts Payable, Current: $6 M (35%)
Accrued Liabilities, Current: $15 M (-10%)
Liabilities, Current: $34 M (40%)
Long-term Debt, Excluding Current Maturities: $252 M (-3%)
Other Liabilities, Noncurrent: $3 M (-5%)
Liabilities: $291 M (0%)
Common Stock, Value, Issued: $45 Th (12%)
Common Stock, Shares, Issued: $45 M (13%)
Additional Paid in Capital, Common Stock: $698 M (3%)
Retained Earnings (Accumulated Deficit): $762 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $254 Th (243%)
Stockholders' Equity (Parent): $63 M (0%)
Liabilities and Equity: $227 M (-9%)
Revenue: $9 M (-45%)
Operating Income/Loss: $18 M (-56%)